A COMPARISON OF KU0063794, A DUAL MTORC1 AND MTORC2 INHIBITOR, AND TEMSIROLIMUS IN PRECLINICAL RENAL CELL CARCINOMA MODELS

被引：0
|
作者：
Zhang, Hao
Berel, Dror
Wang, Yanping
Figlin, Robert
Kim, Hyung
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.359
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：E121 / E122
页数：2
相关论文
共 50 条
  • [21] Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
    Pan, Xiao-dong
    Gu, Dong-hua
    Mao, Jia-Hui
    Zhu, Hua
    Chen, Xinfeng
    Zheng, Bing
    Shan, Yuxi
    PLOS ONE, 2017, 12 (03):
  • [22] mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study
    Kawasaki, Goro
    Naruse, Tomofumi
    Furukawa, Kohei
    Umeda, Masahiro
    ANTICANCER RESEARCH, 2018, 38 (03) : 1623 - 1628
  • [23] Langerhans cell homeostasis in mice is dependent on mTORC1 but not mTORC2 function
    Kellersch, Bettina
    Brocker, Thomas
    BLOOD, 2013, 121 (02) : 298 - 307
  • [24] mTORC1 and mTORC2 differentially promote natural killer cell development
    Yang, Chao
    Tsaih, Shirng-Wern
    Lemke, Angela
    Flister, Michael J.
    Thakar, Monica S.
    Malarkannan, Subramaniam
    ELIFE, 2018, 7
  • [25] Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model
    Mohamed Salama
    Mahmoud Elhussiny
    Alshimaa Magdy
    Ahmed G. Omran
    Aziza Alsayed
    Ramy Ashry
    Wael Mohamed
    Metabolic Brain Disease, 2018, 33 : 583 - 587
  • [26] Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model
    Salama, Mohamed
    Elhussiny, Mahmoud
    Magdy, Alshimaa
    Omran, Ahmed G.
    Alsayed, Aziza
    Ashry, Ramy
    Mohamed, Wael
    METABOLIC BRAIN DISEASE, 2018, 33 (02) : 583 - 587
  • [27] Discovery of OSI-027: An imidazotriazine-based orally efficacious dual inhibitor of mTORC1 and mTORC2
    Dong, Hanqing
    Bhagwat, Shripad V.
    Beard, David
    Bharadwaj, Apoorba
    Bittner, Mark A.
    Chen, Xin
    Coate, Heather
    Cooke, Andrew
    Gokhale, Prafulla
    Kahler, Jennifer
    Mantis, Christine
    Mulvihill, Mark J.
    Panicker, Bijoy
    Tavares-Greco, Paula A.
    Volk, Brian
    Wang, Jing
    Werner, Douglas S.
    Yao, Yan
    Arnold, Lee D.
    Pachter, Jonathan A.
    Wild, Robert
    Epstein, David
    Crew, Andrew P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [28] Characterization of AZD8055, a potent selective inhibitor of mTORC1 and mTORC2 kinase
    Chresta, Christine
    Davies, Barry
    Harding, Tom
    Hickson, Ian
    Cosulich, Sabina
    Critchlow, Susan
    Sini, Patrizia
    James, Dominic
    Malagu, Karine
    Hummersone, Marc
    Smith, Graeme
    Pass, Martin
    Guichard, Sylvie
    CANCER RESEARCH, 2009, 69
  • [29] First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
    Banerji, U.
    Aghajanian, C.
    Raymond, E.
    Kurzrock, R.
    Blanco-Codesido, M.
    Oelmann, E.
    Grinsted, L.
    Burke, W.
    Kaye, S. B.
    Naing, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma
    Neil, Jayson
    shannon, Craig
    Mohan, Avinash
    Laurent, Dimitri
    Murali, Raj
    Jhanwar-Uniyal, Meena
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (03) : 1045 - 1052
12345